Vernalis' collaboration with Tris
Latest status of the programmes for the US prescription market.
Explore Commercial Pipeline
In October 2015, Vernalis also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older and re-launched the product in Q4 2016.
Read more: Moxatag®
T: 0118 938 0000 F: 0118 938 0001Contact informationMaps and directionsContact form
To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and firstname.lastname@example.org or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch